ignorance from some it would appear..., page-5

macrae12...

BIT and CTF's HIV products are completely different and as such, are targeting completely different treatment regimes.

CTF are looking to develop Citrofresh as a topical treatment for both human and animal use...or for other external applications such as non-toxic antiseptic sprays. Importantly, it may also fill the void left from the removal from the market of noxonol-9, which until recently in many contries, was the only widely used form of protection from HIV and other STD's transfer via sexual intercourse.

On the other hand, BIT's HIV drug; BIT225 is designed to inhibit the replication of the HIV virus via mechanical means...that is, the drug doesn't actually kill the virus, instead it simply inhibits it's ability to bud (or replicate).

In actual fact, it is quite possible that both BIT and CTF could find their respective products working in tandem as some kind of overall treatment plan.

Cheers!